The mouse passive‐transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Annals of the New York Academy of Sciences

• Publication date

  2018-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/nyas.13513PMID 29125188
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.

  2017cited by this paper
• Are You Smarter Than a Teenager? Maybe Not When It Comes to Reinforcement Learning.

  2016cited by this paper
• Reversible Recruitment of a Homeostatic Reserve Pool of Synaptic Vesicles Underlies Rapid Homeostatic Plasticity of Quantal Content

  2016cited by this paper
• Enzymatic Activity of the Scaffold Protein Rapsyn for Synapse Formation.

  2016cited by this paper
• Faculty Opinions recommendation of Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction.

  2016cited by this paper
• 3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies

  2016cited by this paper
• Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models.

  2015cited by this paper
• Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravis

  2015cited by this paper
• Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling

  2015cited by this paper
• Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.

  2015cited by this paper
• Crosstalk between Agrin and Wnt signaling pathways in development of vertebrate neuromuscular junction

  2014cited by this paper
• Effects of the ß2-Adrenoceptor Agonist, Albuterol, in a Mouse Model of Anti-MuSK Myasthenia Gravis

  2014cited by this paper
• Caspase-3 cleavage of dishevelled induces elimination of postsynaptic structures.

  2014cited by this paper
• Muscle‐specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction

  2014cited by this paper
• Altered Active Zones, Vesicle Pools, Nerve Terminal Conductivity, and Morphology during Experimental MuSK Myasthenia Gravis

  2014cited by this paper
• Collagen Q is a Key Player for Developing Rational Therapy for Congenital Myasthenia and for Dissecting the Mechanisms of Anti-MuSK Myasthenia Gravis

  2014cited by this paper
• DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction

  2014cited by this paper
• Pyridostigmine but not 3,4‐diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle‐specific kinase autoantibody

  2013cited by this paper
• MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4

  2013cited by this paper
• MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters

  2013cited by this paper
• Muscle‐specific kinase antibodies: A novel cause of peripheral nerve hyperexcitability?

  2013cited by this paper
• Structure and superorganization of acetylcholine receptor–rapsyn complexes

  2013cited by this paper
• Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.

  2012cited by this paper
• Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.

  2012cited by this paper
• Biglycan Is an Extracellular MuSK Binding Protein Important for Synapse Stability

  2012cited by this paper
• Rapsyn mediates subsynaptic anchoring of PKA type I and stabilisation of acetylcholine receptor in vivo

  2012cited by this paper
• 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis.

  2012cited by this paper
• Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.

  2012cited by this paper
• Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis.

  2012cited by this paper
• Neuregulin-1 potentiates agrin-induced acetylcholine receptor clustering through muscle-specific kinase phosphorylation

  2012cited by this paper
• Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice.

  2011cited by this paper
• Skeletal Muscle IP3R1 Receptors Amplify Physiological and Pathological Synaptic Calcium Signals

  2011cited by this paper
• Neuregulin/ErbB regulate neuromuscular junction development by phosphorylation of α-dystrobrevin

  2011cited by this paper
• Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok‐7 myasthenia

  2011cited by this paper
• MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity

  2011cited by this paper
• Anti-MuSK autoantibodies block binding of collagen Q to MuSK

  2011cited by this paper
• Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts

  2011cited by this paper
• Spotlight on the July 5 Issue

  2011cited by this paper
• ColQ Controls Postsynaptic Differentiation at the Neuromuscular Junction

  2010cited by this paper
• Patient autoantibodies deplete postsynaptic muscle‐specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice

  2010cited by this paper
• Clinical findings in MuSK‐antibody positive myasthenia gravis: A U.S. experience

  2010cited by this paper
• The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization.

  2010cited by this paper
• Activity-dependent regulation of the binomial parameters p and n at the mouse neuromuscular junction in vivo.

  2010cited by this paper
• Immunoglobulin G4: an odd antibody

  2009cited by this paper
• Neural agrin increases postsynaptic ACh receptor packing by elevating rapsyn protein at the mouse neuromuscular synapse

  2008cited by this paper
• Lrp4 is a receptor for Agrin and forms a complex with MuSK.

  2008cited by this paper
• Muscle-Specific Receptor Tyrosine Kinase Endocytosis in Acetylcholine Receptor Clustering in Response to Agrin

  2008cited by this paper
• Anti‐MuSK patient antibodies disrupt the mouse neuromuscular junction

  2008cited by this paper
• LRP4 serves as a coreceptor of agrin.

  2008cited by this paper
• HSP90 beta regulates rapsyn turnover and subsequent AChR cluster formation and maintenance.

  2008cited by this paper
• MuSK controls where motor axons grow and form synapses

  2008cited by this paper
• Identification of a Motif in the Acetylcholine Receptor β Subunit Whose Phosphorylation Regulates Rapsyn Association and Postsynaptic Receptor Localization

  2008cited by this paper
• Regulation of synaptic growth and maturation by a synapse-associated E3 ubiquitin ligase at the neuromuscular junction

  2007cited by this paper
• Rapsyn interaction with calpain stabilizes AChR clusters at the neuromuscular junction.

  2007cited by this paper
• Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis.

  2006cited by this paper
• Induction of myasthenia by immunization against muscle-specific kinase.

  2006cited by this paper
• Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a Cdk5-dependent mechanism.

  2005cited by this paper
• Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter.

  2005cited by this paper
• Detection and characterization of MuSK antibodies in seronegative myasthenia gravis

  2004cited by this paper
• Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction

  2003cited by this paper
• Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

  2003cited by this paper
• Split Tolerance in a Novel Transgenic Model of Autoimmune Myasthenia Gravis1

  2002cited by this paper
• Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

  2001cited by this paper
• Src-Class Kinases Act within the Agrin/MuSK Pathway to Regulate Acetylcholine Receptor Phosphorylation, Cytoskeletal Anchoring, and Clustering

  2001cited by this paper
• Src, Fyn, and Yes Are Not Required for Neuromuscular Synapse Formation But Are Necessary for Stabilization of Agrin-Induced Clusters of Acetylcholine Receptors

  2001cited by this paper
• Agrin-induced Activation of Acetylcholine Receptor-bound Src Family Kinases Requires Rapsyn and Correlates with Acetylcholine Receptor Clustering*

  2001cited by this paper
• Dimerization of the Muscle-specific Kinase Induces Tyrosine Phosphorylation of Acetylcholine Receptors and Their Aggregation on the Surface of Myotubes*

  1998cited by this paper
• The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo.

  1996cited by this paper
• Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury.

  1995cited by this paper
• Acetylcholine release in myasthenia gravis: Regulation at single end‐plate level

  1995cited by this paper
• Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha‐bungarotoxin‐treated rats.

  1992cited by this paper
• The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain

  1991cited by this paper
• Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.

  1986cited by this paper
• Windscreen injuries and seat belts.

  1983cited by this paper
• Distribution of acetylcholine receptors at frog neuromuscular junctions with a discussion of some physiological implications.

  1978cited by this paper
• Myasthenia gravis: passive transfer from man to mouse

  1975cited by this paper
• Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs

  1975cited by this paper
• Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis.

  1975cited by this paper
• Study of long‐term anticholinesterase therapy

  1973cited by this paper

• Cell models for studying myasthenia gravis.

  2025cites this paper
• Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.

  2023cites this paper
• Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis?

  2022cites this paper
• Neurologic Diseases

  2021cites this paper
• Management of Juvenile Myasthenia Gravis

  2020influential citation
• 242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019.

  2020cites this paper
• Myasthenia Gravis and Congenital Myasthenic Syndromes.

  2019cites this paper
• Immunologic Disorders of Neuromuscular Junction and Muscle

  2019cites this paper
• Seasonal comparison of the neuromuscular junction morphology of Bufo marinus

  2019cites this paper
• Serological and experimental studies in different forms of myasthenia gravis

  2018cites this paper